🇺🇬 Uganda Prävalenz von Weiblicher Genitalverstümmelung
Uganda Prävalenz von Weiblicher Genitalverstümmelung was 0.30 in 2016, down 78.6% from 2011, according to World Bank data. The 10-year average is 0.77. Historical data available from 2006 to 2016 (3 data points). The all-time high was 1.40 in 2011.
Source: World Bank World Development Indicators • 2006–2016 • 3 data points • Health
Latest Value
0.30
2016
Year-on-Year
-78.6%
vs 2011
10-Year Average
0.77
2007–2016
Range
High: 1.40 (2011)
Low: 0.30 (2016)
Uganda Prävalenz von Weiblicher Genitalverstümmelung (%) — 2006 to 2016
Loading chart...
About this Indicator
Percentage of women aged 15–49 who have gone through partial or total removal of the female external genitalia or other injury to the female genital organs for cultural or other non-therapeutic reasons.
Historical Data Table
| Year | Value |
|---|---|
| 2016 | 0.30 |
| 2011 | 1.40 |
| 2006 | 0.60 |
Embed this chart
Copy and paste this code to embed the chart on your website:
<iframe src="https://nationstat.com/de/country/uganda/female-genital-mutilation-prevalence" width="800" height="500" frameborder="0"></iframe>Compare with Other Countries
🇧🇯Benin
9.202014
🇧🇫Burkina Faso
56.102021
🇨🇫Zentralafrikanische Republik
21.602019
🇨🇮Elfenbeinküste
36.702016
🇨🇲Kamerun
1.402004
🇩🇯Dschibuti
90.102019
🇪🇬Ägypten
87.202015
🇪🇷Eritrea
83.002010
🇪🇹Äthiopien
65.202016
🇬🇭Ghana
2.402018
🇬🇳Guinea
94.502018
🇬🇲Gambia
72.602020
🇬🇼Guinea-Bissau
52.102019
🇮🇶Irak
7.402018
🇰🇪Kenia
14.802022
🇱🇷Liberia
31.802020
🇲🇻Malediven
12.902017
🇲🇱Mali
88.602018
🇲🇷Mauretanien
63.902021
🇳🇪Niger
2.002012
🇳🇬Nigeria
15.102021
🇸🇩Sudan
86.602014
🇸🇳Senegal
20.102023
🇸🇱Sierra Leone
83.002019
🇸🇴Somalia
99.202020
🇹🇩Tschad
34.102019
🇹🇬Togo
3.102017
🇹🇿Tansania
8.202022
🇺🇬Uganda
0.302016
🇾🇪Jemen
18.502013
Related Indicators
Erwachsene (15+ Jahre) und Kinder (0-14 Jahre) kürzlich mit HIV infiziert
37.0K
2024
Erwachsene (15-49 Jahre) kürzlich mit HIV infiziert
30.0K
2024
Jugendliche Fertilitätsrate (Geburten pro 1000 Frauen, 15-19 Jahre)
107.0
2023
Abdeckung antiretroviraler Therapie für PMTCT (% schwangere mit HIV)
100.0
2024
Abdeckung der antiretroviralen Therapie (% HIV-positive Personen)
85.0
2024